SHENZHEN, CHINA - Media OutReach Newswire - 23 July 2026 - Nanyang Optical Co. Pte Ltd (In Liquidation) is inviting expressions of interest from optical retailers, distributors, wholesalers, exporters, and trade buyers for the acquisition of its inventory through a tender sale process.
The inventory, currently located in Shenzhen, China, presents an opportunity for businesses in the optical industry to acquire a substantial range of products suitable for retail, wholesale, and export markets.
Available inventory includes:
- Optical frames
- Sunglasses
- Optical and related inventory
Interested parties are invited to obtain detailed inventory listings and tender documentation and submit offers in accordance with the tender sale process.
This opportunity may be of interest to companies seeking to expand their product offerings, replenish inventory, or secure eyewear stock for regional and international markets.
For enquiries, inventory listings, and tender documents, please contact:
Robert Khan & Co Pte Ltd
Tel: +65 6333 5668
WhatsApp: +65 8223 0954
WeChatID: RobertKhanCo
Email: tender@robertkhanco.com
Website: robertkhanco.com
Hashtag: #RobertKhanCo
https://robertkhanco.com/
https://www.linkedin.com/company/105576231/admin/dashboard/
https://x.com/robertkhan
https://www.facebook.com/robertkhancosg#
Wechat: RobertKhanCo
https://www.instagram.com/rkco_pte_ltd
The issuer is solely responsible for the content of this announcement.
Robert Khan & Co Pte Ltd
We are a team of International Business Assets Consultants focused on the marketing & valuation of unique & interesting projects. We believe that "Valuation is more Art than Science". Every asset, machine or even a piece of jewellery is unique and imbued with their own story. With over 20 years of experience uncovering unique stories across an exhaustive range of asset classes, we offer our clients our experienced eye, keen ears and interested heart to curate projects and realise their project objectives. Our services include valuation, marketing & sale of various asset classes locally and internationally.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
ROCHESTER, MINN., US / SINGAPORE – Media OutReach Newswire – 23 September 2026 – Mayo Clinic Laboratories and Pathology Asia Holdings (PAH) have announced a strategic investment and collaboration aimed at expanding access to advanced diagnostics and precision medicine across Southeast Asia, Australia and New Zealand.
Mayo Clinic Laboratories and PAH are deepening a long-term relationship that brings together Mayo's global clinical and diagnostic expertise with the regional healthcare network, capabilities and market knowledge of PAH and its genomics subsidiary, LifeStrands Genomics. William Morice II, M.D., Ph.D., president and CEO of Mayo Clinic Laboratories, has been appointed Scientific Adviser to PAH.
Genomics is a central focus of the collaboration, delivered through LifeStrands Genomics. Mayo Clinic Laboratories and LifeStrands Genomics will work together to broaden access to advanced molecular and genomic testing across Southeast Asia, Australia and New Zealand, with applications spanning the identification of genetic conditions, disease risk assessment, diagnosis, and treatment planning, enabling healthcare providers to integrate clinically relevant genomic insights into more personalised patient care.
LifeStrands Genomics will operate as "LifeStrands in collaboration with Mayo Clinic Laboratories" in certain markets, reflecting the organisations' shared commitment to expanding access to advanced genomic testing and precision medicine across the region.
Together, the organisations will pursue joint scientific initiatives, education and thought leadership to support the integration of genomics into patient care. "Healthcare providers across Southeast Asia, Australia and New Zealand are increasingly seeking advanced diagnostic solutions to guide patient care," said Dr. Morice. "Our collaboration with PAH and LifeStrands Genomics reflects our commitment to a long-term strategic relationship that unites complementary strengths in laboratory diagnostics and genomics. Through this collaboration, we are bringing advanced diagnostic capabilities closer to patients and equipping healthcare providers with the insights needed to deliver personalised care."
"Mayo Clinic Laboratories' investment marks an important milestone in our relationship and a strong foundation for the next phase of diagnostic innovation across the region," Christopher Ting, M.D., founder and CEO of Pathology Asia Holdings, added. "Combining Mayo Clinic Laboratories' global clinical and scientific expertise with PAH's regional diagnostic capabilities and network will enable us to broaden access to advanced testing and increase access to genomics and precision medicine capabilities across Southeast Asia, Australia and New Zealand."
Hashtag: #MayoClinicLaboratories #PathologyAsia #LifeStrands #LifeStrandsGenomics #LifeStrandsGenomicsAustralia #DNALAB #DNALaboratories #PrecisionMedicine
https://www.lifestrandsgx.com/
https://www.linkedin.com/company/lifestrandsgx/
The issuer is solely responsible for the content of this announcement.
Mayo Clinic Laboratories
Mayo Clinic Laboratories, the global leader in turning test results into clinical answers, provides advanced testing and pathology services for healthcare organisations worldwide in partnership with Mayo Clinic's Department of Laboratory Medicine and Pathology. Mayo Clinic Laboratories offers more than 4,400 tests and pathology services, delivering specialised diagnostic expertise to help healthcare providers make informed decisions and improve patient care.
Pathology Asia
Pathology Asia is a leading regional provider of pathology and laboratory diagnostics services, with operations across Singapore, Malaysia, Indonesia, Thailand, Vietnam, the Philippines and Australia. Its network encompasses established diagnostics brands including Innoquest, Singapore Diagnostics, TissuPath and Safework Health, as well as its specialist genomics businesses, LifeStrands Genomics and DNA Laboratories. Pathology Asia delivers a comprehensive range of pathology, molecular and genomic testing services to healthcare providers, hospitals and patients across the region through its network of internationally accredited laboratories.
LifeStrands Genomics
LifeStrands Genomics is a leading Asia-Pacific clinical genomics company comprising three specialist laboratories: LifeStrands Genomics Singapore, LifeStrands Genomics Australia, and DNA Laboratories. Together, the group provides advanced molecular and genomic testing across oncology, reproductive health, inherited disorders and wellness. Operating through CAP- and ISO 15189-accredited laboratories, LifeStrands Genomics delivers clinically actionable insights that empower healthcare professionals to make informed decisions, advance personalised care and improve patient outcomes.
** This press release is distributed by Media OutReach Newswire through automated distribution system, for which the client assumes full responsibility. **
